Meta-Analysis

A meta-analysis is a quantitative statistical methodology that pools numerical data from multiple independent primary studies identified through a systematic review. By mathematically combining sample sizes, meta-analyses increase statistical power, generate precise pooled effect estimates (such as Odds Ratios, Relative Risks, or Weighted Mean Differences), and evaluate statistical heterogeneity (I2 statistic) across study findings.

Meta-analyses of incretin trials in diabetes confirmed that GLP-1 RAs reduce all-cause mortality, cardiovascular death, and chronic kidney disease progression across thousands of combined patients.

Individual trials can mislead through chance, especially for less common outcomes such as deaths or heart attacks. Pooling trials gives more precise estimates. A 2021 meta-analysis of eight cardiovascular outcome trials with 60,080 people with type 2 diabetes found that GLP-1 receptor agonists reduced major adverse cardiovascular events by 14% and all-cause mortality by 12%, with no increase in severe hypoglycaemia, retinopathy or pancreatic adverse effects.

A meta-analysis is only as good as the studies it includes. Pooling small, biased or poorly reported studies produces a precise-looking number that can still be wrong. Reviewers also need to check how much results vary between studies, often summarised with the I² statistic. Large, unexplained differences between trials mean a single pooled figure may hide more than it reveals.

Peptide marketing sometimes borrows the authority of meta-analyses carried out on a whole drug class or on approved products. Always check who was studied, what was compared and which products the included trials actually used. Results from placebo-controlled trials of approved GLP-1 drugs in type 2 diabetes say nothing about unapproved analogues or grey-market versions.

“Any meta-analysis outranks any single trial”

A well-conducted meta-analysis of high-quality randomised trials sits near the top of the evidence hierarchy. A meta-analysis of weak or inconsistent studies does not. A single large, well-designed randomised trial can be more trustworthy than a pooled analysis of small, biased studies, so the quality of the inputs matters as much as the method.

“Pooling many small studies fixes their weaknesses”

Combining studies increases statistical power, but it cannot remove shared biases such as poor randomisation, lack of blinding or selective publication. If every included study overstates an effect, the pooled result will too. This is why careful meta-analyses assess risk of bias and test whether conclusions change when weaker studies are removed.

“A systematic review and a meta-analysis are the same thing”

A systematic review is a structured search for, and appraisal of, all relevant studies on a question. A meta-analysis is the statistical step that combines their numerical results. Many systematic reviews include a meta-analysis, but some do not, often because the studies are too different or too few to pool sensibly.

What is a meta-analysis in simple terms?

A meta-analysis is a study of studies. Researchers gather the results of several trials that asked the same question, usually found through a systematic review, and combine them statistically to produce one overall estimate. Because it draws on more participants, the pooled result is usually more precise than any single study.

What does I² mean in a meta-analysis?

I² is a statistic describing how consistent the results of the included studies are. It estimates the percentage of the variation between study results that reflects genuine differences rather than chance. A low I² suggests the studies broadly agree; a high I² signals substantial inconsistency, which the authors should investigate and explain.

Do GLP-1 drugs reduce heart attack and stroke risk?

In people with type 2 diabetes, a 2021 meta-analysis of eight large placebo-controlled outcome trials found that GLP-1 receptor agonists reduced the combined risk of cardiovascular death, heart attack and stroke by 14%. They also reduced hospital admission for heart failure and a composite kidney outcome. These findings apply to the approved drugs studied, in that population.

Is there a meta-analysis of BPC-157 in humans?

No human meta-analysis is possible yet, because there is almost no human data to pool. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 35 preclinical studies and only one clinical study, a small retrospective report, and no clinical safety data. Claims of strong human evidence for BPC-157 are not supported.